Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Return on Sales (2021 - 2025)

Lyra Therapeutics has reported Return on Sales over the past 5 years, most recently at 993.0% for Q4 2025.

  • Quarterly results put Return on Sales at 993.0% for Q4 2025, down 94047.0% from a year ago — trailing twelve months through Dec 2025 was 72.66% (down 1175.0% YoY), and the annual figure for FY2025 was 72.66%, down 1175.0%.
  • Return on Sales for Q4 2025 was 993.0% at Lyra Therapeutics, down from 239.36% in the prior quarter.
  • Over the last five years, Return on Sales for LYRA hit a ceiling of 25.45% in Q1 2022 and a floor of 1292.91% in Q4 2022.
  • Median Return on Sales over the past 5 years was 48.48% (2025), compared with a mean of 221.6%.
  • Biggest five-year swings in Return on Sales: crashed -124266bps in 2022 and later soared 118910bps in 2023.
  • Lyra Therapeutics' Return on Sales stood at 50.25% in 2021, then plummeted by -2473bps to 1292.91% in 2022, then surged by 92bps to 103.81% in 2023, then skyrocketed by 49bps to 52.53% in 2024, then crashed by -1790bps to 993.0% in 2025.
  • The last three reported values for Return on Sales were 993.0% (Q4 2025), 239.36% (Q3 2025), and 40.64% (Q2 2025) per Business Quant data.